Ivenix Names Jorgen B. Hansen as Chief Executive Officer

Ivenix Names Jorgen B. Hansen as Chief Executive Officer

 Medical device and healthcare industry leader joins Ivenix to lead smart infusion pump commercialization

BOSTON, Jan 13, 2020 — Ivenix today announced the appointment of Jorgen B. Hansen as CEO and a member of Ivenix’s board of directors. Hansen has more than 25 years of global healthcare experience.

The CEO appointment comes at a time of great momentum for Ivenix, which received its 510(k) clearance from the U.S. Food and Drug Administration (FDA) in 2019. The infusion system was cleared under the FDA’s new regulatory guidance, adopted in 2014 to address recurring safety problems associated with existing infusion pumps.

“We are thrilled to have someone of Jorgen’s caliber leading Ivenix as we build our business and execute our market launch,” said Ivenix Board Chairman John Douglass. “Jorgen brings extensive market knowledge, strategy, product and business development experience at this important time in the company’s evolution. He is a proven medical technology leader with deep expertise in commercialization strategies that successfully drive company growth.”

Prior to joining Ivenix, Hansen spent seven years serving in leadership positions at the fast-growing Cantel Medical Corporation (NYSE:CMD), most recently as president and CEO, heading the company’s rapid organic growth globally and overseeing the execution of more than 25 acquisitions. Before that, he served as senior vice president for global strategy and marketing, business development, science and innovation at ConvaTec. Hansen also held leadership roles at Coloplast A/S, including as senior vice president of global operations, business unit head and general manager in China. He holds degrees in mechanical engineering from the Denmark Technical University and international commerce from the Copenhagen Business School.

“I am incredibly excited about the opportunity to join Ivenix, especially given the company’s powerful momentum following FDA clearance of its novel infusion system,” said Ivenix CEO Jorgen B. Hansen. “The technology has massive market potential and I look forward to leading the company to realize its vision of eliminating infusion errors, improving patient outcomes and reducing related healthcare costs.”

About Ivenix
Ivenix is a medical technology company with a vision to eliminate infusion-related patient harm. The company was founded to develop innovative, smart solutions that revolutionize infusion delivery and management. Ivenix designed an infusion system from the ground up to streamline medication delivery and bring legacy technology into the digital age. The Ivenix Infusion System includes a large-volume infusion pump supported by a robust infusion management system designed to set new standards in usability, medication precision and interoperability.

For more information, visit ivenix.com.